

DEVELOPING EFFECTIVE HTA STRUCTURE

WITHIN HEALTHCARE SYSTEM

LESSON LEARNT FROM THAILAND

Netnapis Suchonwanich


Advisor of HITAP, Thailand

Former Deputy Secretary General of NHSO, Thailand



Health Insurance Schemes


Gradual insurance coverage expansion given strong health care infrastructure



- General tax
- Non-contributory
- Fee for service (OP),DRG (IP)
- Comprehensive benefit package

- Payroll tax
- Tripartite contribution -
- Capitation,DRG
- Comprehensive benefit package


- General Tax
- Non-contributory
- Capitation, global budget and DRG
- Comprehensive benefit package








Proposed versus approved capitation rate for UCS Baht per capita nominal term 2002-2010




3109.78 Baht in 2017 equivalent to 94.23 USD for a basic package



The balanced perspectives




Policy makers need more evidences






Strategies for increasing the value for money








Role of HTA in Thailand


Using HTA in benefit package decisions in Thailand



HTA = Health Technology Assessment NLEM = National list of essential medicines



Benefit Package of the Universal Coverage Scheme



SCBP = Sub-committee for the development of Benefits Package and Service Delivery NHSB = National Health Security Board


Three major problems:

- I. There were a large number of issues proposed by various groups of stakeholders to the SCBP.
- II. The presentations made to the SCBP varied in the quality of evidences to support the proposals wherein some presentations were based on expert opinions or case studies.
- III. It was evident that there was a bias toward power groups who could lobby the Secretariat.

UCBP = The Development of the Universal Health Coverage Benefit Package Project

HITAP = Health Intervention and Technology assessment Program IHPP = International Health Policy Program

Benefit Package of the Universal Coverage Scheme




Three major problems:

- I. There were a large number of issues proposed by various groups of stakeholders to the SCBP.
- II. The presentations made to the SCBP varied in the quality of evidences to support the proposals wherein some presentations were based on expert opinions or case studies.
- III. It was evident that there was a bias toward power groups who could lobby the Secretariat.

SCBP = Sub-committee for the development of Benefits Package and Service Delivery NHSB = National Health Security Board **UCBP** = The Development of the Universal Health Coverage Benefit Package Project

HITAP = Health Intervention and Technology assessment Program IHPP = International Health Policy Program

Key Developments of Benefit Package under UCs



SCBP = Sub-committee for the development of Benefits Package and Service Delivery

HWG = Health Economics Working Group



Why do we need "HTA process guideline"?







Thailand HTA process guidelines



Step 1 *Stakeholders' meeting on scope of the study



Step 4

*Stakeholders' meeting on the preliminary results of the study



Step 2

Researchers present proposal to the Health Economic Working Group



Step 5

Research quality inspection: internal and external reviewers



Step 3 Researchers conduct studies



Step 6

Researchers present the results to the Health Economic Working Group

Step 7

Writing up the study report that include executive summary and policy recommendation

*Stakeholders include medicine nominators, practitioners and all clinical experts in the field, and pharmaceutical representatives



Topic nomination meetings of civil groups and lay citizens







The Development of the Universal Health Coverage Benefit Package Project

Between 2010-2015

129 Nominated 63 Selected for assessment

The Number of Nominated and Selected Topics











UCBP process 2018




Using HTA in benefit package decisions in Thailand




HTA = Health Technology Assessment NLEM = National list of essential medicines

17






Priority setting step before final approval





Cost-Effectiveness threshold and price negotiation



What HTA provided for UCS development

- Evidence of cost effectiveness
- Value for money
 - Incremental cost-effectiveness ratio (ICER)
 - Cost-effectiveness threshold = 160,000 THB/QALY (5,000 USD)
- Budget impact compared current practice and new intervention
- Feasibility study
- **o** Simulation the threshold affordable prices for price negotiation
- Equity considerations



Using economic evaluation to inform NLEM development during 2007-2010

	Cost-effectiveness study	Finding	Recommendation
*	HMG-CoA reductase inhibitors	Atorvastatin not cost- effective	Not included atorvastatin in the list
*	Osteoporosis drugs	not cost-effective	Not included in the list
	Acetylcholinesterase inhibitors	not cost-effective	Not included in the list
*	Peginterferon alfa-2a, 2b	cost-effective	Included in the list
*	Tenofovir	cost-effective	Included in the list
*	Oxaliplatin	not cost-effective	Price negotiation and included in the list

Basic of decision making for policy maker

 Subsidy considered on the basis of Cost effectiveness, incremental cost effectiveness ratio (ICER)

→Cost effectiveness is a key, but not sole criterion for listing

- Catastrophic prevention
- Medium to long term budget impact assessment
- Ethical consideration
- Supply side capacity to scale up new interventions
- Equity consideration
- Monitoring and evaluation
 - Accessibility, Efficiency, Quality and Effectiveness in Healthcare

Appraisal results and decision making

Table 4 – The relationship between assessment and appraisal results.							
Policy	Assessment results*						
recommendation	Cost-effective (ICER ≤1 per-capita GDP/QALY)		Not cost-effective (ICER >1 per-capita GDP/QALY)				
	Low budget impact [†]	High budget impact ⁺	Low budget impact	High budget impact			
	 Lamivudine for treatment of people with chronic hepatitis B Intravenous cyclophosphamide + azathioprine for treating severe lupus nephritis Smoking cessation program 		• Imiglucerase for Gaucher type 1	PD-first policy for ESRD			
Not recommended	 Implant dentures for people who have problem with conventional complete dentures 	 Pegylate interferon alpha 2a + ribavirin for treating hepatitis C Absorbent products for urinary and fecal incontinence among disabled and elderly people 	_	 Anti-immunoglobulin E for severe asthma 			

ICER, incremental cost-effectiveness ratio; GDP, gross domestic product; QALY, quality-adjusted life-year; THB, Thai baht.

* Two cost analysis studies, that is, screening for risk factors for leukemia in people living in the industrial areas, and system for screening, treatment, and rehabilitation of alcoholism, are not included in this table.

⁺ High budget impact >THB 200 million per annum; low budget impact \leq THB 200 million per year.

Before using IRP, Thailand must first use HTA to determine the value and prioritize each new product

